ICYMI:Methotrexate and hepatic fibrosis: we must be doing something right Despite methotrexate’s use in rheumatology, and the consequent frequency of patient counselling about it, relatively little is known about what precautions are absolutely required.https://t.co/AMvnQnMUUl https://t.co/aRzsy4ZA8z

ICYMI: New Insights into Uveitis in Spondyloarthritis Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). Read more on RheumNow.https://t.co/JF7TtE8SVJ https://t.co/Sw2b1WX5ko

ICYMI: Diagnosing (Bad) VEXAS: The Experts Speak Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting.https://t.co/oafDX0rJIl https://t.co/UoNpjABLNd

Guselkemab vs. Ustekinumab in PsAhttps://t.co/JCs5VpkyUK https://t.co/OzRtdWtqXp

ICYMI: DORIS - Defining Remission in Lupus Proponents of treat to target in systemic lupus erythematosus (SLE) have all agreed that "remission" should be the goal, but defining remission may be tricky in SLE. Read on...https://t.co/hVfzAtRzgY https://t.co/hSPz1eASzF

ICYMI: Giant Cell Arteritis Novel Treatment Options https://t.co/ywqGZNmHOa https://t.co/2hLESL1RjO

Telemedicine Upside Interview with Dr. Alvin Wells Dr. Jack Cush interviews telemedicine guru, Dr. Alvin Wells, on the current state of telemedicine and what the future holds for telehealth in rheumatology.https://t.co/iOpKqjIVuP https://t.co/emseMx4iZ0

TNF inhibitors and radiographic progression in axSpA

Save

A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axSpA, whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.

Read Article

Telemedicine Upside Interview with Dr. Alvin Wells

Save

In spite of the transformative growth of telemedicine during the COVID-19 pandemic, rheumatologists use of telemedicine is waning, much like the use of masks. Dr. Jack Cush interviews telemedicine guru, Dr. Alvin Wells, on the current state of telemedicine and what the future holds for telehealth in rheumatology.

Read Article

Spondyloarthritis Panel Discussion: ACR21 Meeting Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood discuss abstracts #0562, #1919, #0907, #0364 and #0919 @synovialjoints @doctorRBC @uptoTate @RHEUMarampa @AkhilSoodMD https://t.co/g0ARcP26wt https://t.co/8Lpwpf6AI1

Watch Now: Can We Stop Medication in Systemic JIA?https://t.co/yRIb70YVME https://t.co/EJ2PmC6xKY

Third Time's the Charm - COVID Vaccination While on Rituximabhttps://t.co/3j0KeQtzw1 https://t.co/YvgpaDX7tv

Rheumatoid arthritis (RA) has been linked to a higher risk of dementia and cognitive dysfunction, but interestingly this association has diminished in the last few decades with aggressive DMARD and targeted therapies.https://t.co/T1feTkSKQv https://t.co/XElvgsGC0E

Best of PsA Day 4 - MACE in PsAhttps://t.co/NTM1GR7d5W https://t.co/ZxPJ8jDXhD

Watch: Rheumatic Diseases Can Take your Breath Awayhttps://t.co/7Butbt50N3 https://t.co/4VV1myDXWV

Rheumatoid Arthritis, Dementia and Cognitive Dysfunction

Save

Rheumatoid arthritis (RA) has been linked to a higher risk of dementia and cognitive dysfunction, but interestingly this association has diminished in the last few decades with aggressive DMARD and targeted therapies..

Read Article

Methotrexate and hepatic fibrosis: we must be doing something right

Save

Methotrexate may be a rheumatologist’s best friend, but a key part of counselling any patient about its use has always been the risk of hepatotoxicity.

Read Article

Might Tofacitinib Reduce Malignancy Risk with Patients with RA?https://t.co/xDnbPvjFDj https://t.co/yVcftm9Vwz

Watch: TNFi in axSpAhttps://t.co/uS01KNDgIH https://t.co/eb0W3fBKhq